DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Apr 22 2010

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will host a DDW2010 Investor Event on Monday, May 3 2010 from 9:00 p.m. to 10:00 p.m. Central Time (10:00 p.m. to 11:00 p.m. ET). A live webcast of the event will be available on the Company's website at www.Salix.com.

Bill Forbes, Pharm. D., Executive Vice President, Research and Development and Chief Development Officer, Salix, will host the event. The event will provide an update and discussion on the TARGET 1 and TARGET 2 Phase 3 trials which evaluated the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with Non-constipation Irritable Bowel Syndrome.

Presenters include:

• Bill Forbes, Pharm.D., Executive Vice President, Research and Development and Chief Development Officer, Salix Pharmaceuticals
• Mark Pimentel, MD, FRCP (C), Associate Professor of Medicine, Geffen School of Medicine at UCLA, Director, GI Motility Program, Cedars-Sinai Medical Center

• Philip Schoenfeld, MD, MSED, MSc, Associate Professor, Department of Internal Medicine, Division of Gastroenterology, The University of Michigan